Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) traded up 3% during trading on Thursday . The stock traded as high as $27.82 and last traded at $27.41, with a volume of 366,494 shares. The stock had previously closed at $26.61.

Several research analysts recently weighed in on the stock. Jefferies Group reissued a “buy” rating and set a $61.00 price objective on shares of Alder BioPharmaceuticals in a research note on Tuesday. Brean Capital reissued a “buy” rating on shares of Alder BioPharmaceuticals in a research note on Saturday, April 30th. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $29.00 price objective on the stock in a research note on Wednesday. Leerink Swann reissued an “outperform” rating on shares of Alder BioPharmaceuticals in a research note on Tuesday, March 29th. Finally, Credit Suisse Group AG reissued an “outperform” rating and set a $40.00 price objective on shares of Alder BioPharmaceuticals in a research note on Tuesday, March 29th. Six research analysts have rated the stock with a buy rating, Alder BioPharmaceuticals has an average rating of “Buy” and a consensus price target of $47.40.

The firm’s 50-day moving average price is $27.10 and its 200 day moving average price is $25.24. The company’s market cap is $1.36 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.04. During the same period in the previous year, the company earned ($0.40) EPS. On average, equities research analysts expect that Alder BioPharmaceuticals Inc. will post ($3.25) EPS for the current year.

In other news, VP Jeffrey T. L. Smith sold 16,090 shares of the stock in a transaction dated Friday, June 3rd. The shares were sold at an average price of $30.20, for a total value of $485,918.00. Following the completion of the transaction, the vice president now owns 16,090 shares of the company’s stock, valued at $485,918. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark James Litton sold 6,000 shares of the stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $28.94, for a total transaction of $173,640.00. Following the completion of the transaction, the insider now directly owns 74,567 shares of the company’s stock, valued at approximately $2,157,968.98. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. Janus Capital Management increased its position in Alder BioPharmaceuticals by 391.1% in the third quarter. Janus Capital Management now owns 4,239,855 shares of the biopharmaceutical company’s stock valued at $138,900,000 after buying an additional 3,376,540 shares in the last quarter. Brown Advisory Inc. increased its position in Alder BioPharmaceuticals by 118.8% in the fourth quarter. Brown Advisory Inc. now owns 379,579 shares of the biopharmaceutical company’s stock valued at $12,538,000 after buying an additional 206,108 shares in the last quarter. Wells Fargo & Company MN increased its position in Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock valued at $8,911,000 after buying an additional 200,707 shares in the last quarter. California Public Employees Retirement System increased its position in Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock valued at $2,685,000 after buying an additional 72,600 shares in the last quarter. Finally, Pyrrho Capital Management LP increased its position in Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock valued at $2,081,000 after buying an additional 42,343 shares in the last quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.